These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: the first case in the literature. Sisman G; Erzin Y; Bal K J Crohns Colitis; 2013 Oct; 7(9):e397-8. PubMed ID: 23583098 [No Abstract] [Full Text] [Related]
7. Infliximab-associated psoriasis in children with Crohn's disease may require withdrawal of anti-tumor necrosis factor therapy. Broge T; Nguyen N; Sacks A; Davis M Inflamm Bowel Dis; 2013 Apr; 19(5):E75-7. PubMed ID: 23435403 [No Abstract] [Full Text] [Related]
8. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. Iborra M; Beltrán B; Bastida G; Aguas M; Nos P J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886 [TBL] [Abstract][Full Text] [Related]
9. Infliximab therapy in a patient with refractory ileocolic Crohn's disease and Takayasu arteritis. Calderón R; Estrada S; Ramírez de la Piscina P; Salvador M; Zabaleta S; Enciso C; Delgado E; García-Campos F Rev Esp Enferm Dig; 2010 Feb; 102(2):145-6. PubMed ID: 20361852 [No Abstract] [Full Text] [Related]
10. Guttate psoriasis induced by infliximab in a child with Crohn's disease. Costa-Romero M; Coto-Segura P; Suarez-Saavedra S; Ramos-Polo E; Santos-Juanes J Inflamm Bowel Dis; 2008 Oct; 14(10):1462-3. PubMed ID: 18383177 [No Abstract] [Full Text] [Related]
11. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Tan MH; Gordon M; Lebwohl O; George J; Lebwohl MG Arch Dermatol; 2001 Jul; 137(7):930-3. PubMed ID: 11453813 [TBL] [Abstract][Full Text] [Related]
12. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F; Portela F BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228 [TBL] [Abstract][Full Text] [Related]
13. Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies. Barthel C; Biedermann L; Frei P; Vavricka SR; Kündig T; Fried M; Rogler G; Scharl M Digestion; 2014; 89(3):209-15. PubMed ID: 24853251 [TBL] [Abstract][Full Text] [Related]
14. Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab. Andrisani G; Marzo M; Celleno L; Guidi L; Papa A; Gasbarrini A; Armuzzi A Eur Rev Med Pharmacol Sci; 2013 Oct; 17(20):2831-6. PubMed ID: 24174369 [TBL] [Abstract][Full Text] [Related]
15. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. Oh CJ; Das KM; Gottlieb AB J Am Acad Dermatol; 2000 May; 42(5 Pt 1):829-30. PubMed ID: 10775863 [TBL] [Abstract][Full Text] [Related]
16. Restoration of soluble CD146 in patients with Crohn's disease treated with the TNF-alpha antagonist infliximab. Reumaux D; Bardin N; Colombel JF; Dignat-George F; Duthilleul P; Vermeire S Inflamm Bowel Dis; 2007 Oct; 13(10):1315-7. PubMed ID: 17476677 [No Abstract] [Full Text] [Related]
17. Anti-TNFalpha therapy in a rare case of Crohn's disease: still a panacea. Verburg R; Zelissen P; Rothova A; Siersema PD; Oldenburg B Inflamm Bowel Dis; 2008 Oct; 14(10):1457-60. PubMed ID: 18383178 [No Abstract] [Full Text] [Related]
18. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease. de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M Digestion; 2008; 78(4):195-200. PubMed ID: 19122456 [TBL] [Abstract][Full Text] [Related]
19. [Therapeutic management of plaque psoriasis: the interest of anti-TNFalpha]. Ortonne JP Ann Dermatol Venereol; 2005; 132(8-9 Pt 2):4S6-4S9. PubMed ID: 16335346 [No Abstract] [Full Text] [Related]
20. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system. Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]